Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 283
- Registration Number
- NCT02191202
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Phase 3
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 245
- Registration Number
- NCT02191254
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT02191319
Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT02191865
- Locations
- 🇩🇪
1199.200.49001 Boehringer Ingelheim Investigational Site, Kiel, Germany
Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02191709
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 442
- Registration Number
- NCT02191215
Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Seresis®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT02191787
Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Seresis®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02191813
Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT02192463
Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency
Phase 2
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT02191163
© Copyright 2025. All Rights Reserved by MedPath